HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


Download full text PDF

I. Zolotovskaya, Candidate of Medical Sciences; Professor I. Davydkin, MD Samara State Medical University

The authors evaluate the impact of etoricoxib therapy on the time of course of changes in cognitive deficit, as well as the altered level of cytokines in patients with osteoarthritis.

nonsteroidal antiinflammatory drugs
cognitive functions

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Azizi G., Navabi S., Al-Shukaili A. et al. The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer’s Disease // Sultan Qaboos. Univ. Med. J. – 2015; 15: 305–16.
  2. Mattila J., Soininen H., Koikkalainen J. et al. Optimizing the diagnosis of early Alzheimer’s disease in mild cognitive impairment subjects // J. Alzheimers Dis. – 2012; 32: 969–79.
  3. Chin-Chan M., Navarro-Yepes J., Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases // Front Cell Neurosci. – 2015; 9: 124.
  4. Breitner J., Baker L., Montine T. et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial // Alzheimers Dement. – 2011; 7: 402–11.
  5. Corsi M., Di Raimo T., Di Lorenzo C. et al. Cognitive disability in alzheimer's disease and its management // Clin. Ter. – 2016; 67: 123–6.
  6. Gross A., Mungas D., Leoutsakos J. et al. Alzheimer's disease severity, objectively determined and measured // Alzheimers Dement (Amst). – 2016; 14 (4): 159–68.
  7. Calkins M., Reddy P. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons // Biochem. Biophys. Acta. – 2011; 1812: 507–13.
  8. Orsucci D., Mancuso M., Ienco E. et al. Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer’s disease // Curr. Neurovasc. Res. – 2013; 10: 76–80.
  9. Daneschvar H., Aronson M., Smetana G. Do statins prevent Alzheimer’s disease? A narrative review // Eur. J. Intern. Med. – 2015; 26: 666–9.
  10. Huang Y. Apolipoprotein E and Alzheimer disease // Neurology. – 2006; 66: 79–85.
  11. Erickson M., Banks W. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease // J. Cereb. Blood Flow Metab. – 2013; 33: 1500–13.
  12. Altman R., Asch E., Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association // Arthritis. Rheum. – 1986; 29 (8): 1039–49.
  13. Bellamy N., Buchanan W., Goldsmith C. et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee // J. Rheumatol. – 1988; 15 (12): 1833–40.
  14. Nasreddine Z., Phillips N., Bedirian V. et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment // J. Am. Geriatr. Soc. – 2005; 53: 695–9.
  15. Goldring M., Otero M. Inflammation in osteoarthritis // Curr. Opin. Rheumatol. – 2011; 23 (5): 471–8.
  16. Akagi R., Akatsu Y., Fisch K. et al. Dysregulated circadian rhythm pathway in human osteoarthritis: NR1D1 and BMAL1 suppression alters TGF-v signaling in chondrocytes // Osteoarthritis Cartilage. – 2016; 21: doi: 10.1016/j.joca.2016.11.007. [Epub ahead of print].
  17. Wang X., Hunter D., Xu J. et al. Metabolic triggered inflammation in osteoarthritis // Osteoarthritis and Cartilage. – 2015; 23: 22–30.
  18. Liu-Bryan R. Synovium and the innate inflammatory network in osteoarthritis progression // Curr. Rheumatol. Reports. – 2013; 15: 1–7.
  19. Daheshia M., Yao J. The interleukin 1β pathway in the pathogenesis of osteoarthritis // J. Rheumatol. – 2008; 35: 2306–12.
  20. Shakibaei M., Csaki C., Nebrich S. et al. Resveratrol suppresses interleukin-1β-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis // Biochem. Pharmacol. – 2008; 76: 1426–39.
  21. Holla J., van der Leeden M., Knol D. et al. The association of body-mass index and depressed mood with knee pain and activity limitations in knee osteoarthritis: results from the Amsterdam osteoarthritis cohort // BMC Musculoskelet Disord. – 2013; 14 (1): 296.
  22. Singh J., Lewallen D. Time trends in the characteristics of patients undergoing primary total knee arthroplasty // Arthritis Care Res. – 2013; 66 (6): 897–906.
  23. Martin K., Kuh D., Harris T. et al. Body mass index, occupational activity, and leisure-time physical activity: an exploration of risk factors and modifiers for knee osteoarthritis in the 1946 British birth cohort // BMC Musculoskelet Disord. – 2013; 14: 219.
  24. Murphy S., Lyden A., Phillips K. et al. Subgroups of older adults with osteoarthritis based upon differing comorbid symptom presentations and potential underlying pain mechanisms // Arthritis Res. Ther. – 2011; 13 (4): R135.
  25. Seminskij I.Zh., Serebrennikova S.N., Guzovskaja E.V. i dr. Rol' tsitokinov v patogeneze zabolevanij (soobschenie 2) // Sib. med. zhurn. (Irkutsk). – 2015; 1: 14–7.
  26. Singh D., Chopra K. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke // Pharmacol. Biochem. Behav. – 2014; 120: 33–42.
  27. Huebner J., Landerman L., Somers T. et al. Exploratory secondary analyses of a cognitive-behavioral intervention for knee osteoarthritis demonstrate reduction in biomarkers of adipocyte inflammation // Osteoarthritis Cartilage. – 2016; 24 (9): 1528–34.
  28. Sil S., Ghosh T. Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease // J. Neuroimmunol. – 2016; 291: 115–24. doi: 10.1016/j.jneuroim.2015.12.003